ephron-sparing treatment for small renal masses

Not Applicable

• Conditions: Kidney cancer; Cancer; Renal cancer

• Registration Number: ISRCTN18156881
• Lead Sponsor: Royal Free London NHS Foundation Trust

Brief Summary

2019 Protocol article in https://pubmed.ncbi.nlm.nih.gov/31189686/ protocol (added 26/06/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-04
• Last Update Posted: 27 June 2022
• Study Completion: 2023-06-17

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Inclusion criteria for study cohort:
1. Informed consent
2. Males and females
3. > 18 years of age
4. Diagnosed with renal mass <4 cm in size

Inclusion criteria for randomisation/interventional cohort:
1. Biopsy proven RCC
2. Tumours that are suitable for robot-assisted PN and CO

Exclusion Criteria

Exclusion criteria for study cohort:
1. Any of the above listed inclusion criteria not met
2. Patient unable to provide or indicate informed consent

Exclusion criteria for randomisation/interventional cohort:
Patients with any concurrent medical/surgical condition or indication, which would mean the SMDT recommends one treatment modality is more suitable than another, such as:
1. Myocardial Infarction in preceding 6/12
2. Pulmonary disease not allowing for prolonged anaesthesia
3. Multiple previous abdominal surgery/interventions, making surgical approach high risk
4. Performance status > = 2
5. Metastatic disease
6. Charlson co-morbidity index > 3
7. Patients with multifocal tumours
8. Patients with suspected or diagnosed with inherited kidney cancer susceptibility syndromes
9. Women that are pregnant or breastfeeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified